Progesterone antagonists and progesterone receptor modulators: an overview

[1]  A. Templeton,et al.  Medical abortion at 64 to 91 days of gestation: a review of 483 consecutive cases. , 2003, American journal of obstetrics and gynecology.

[2]  R. Brenner,et al.  Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. , 2003, The Journal of clinical endocrinology and metabolism.

[3]  N. Sidell,et al.  RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. , 2003, The Journal of clinical endocrinology and metabolism.

[4]  K. Fiscella,et al.  Low‐Dose Mifepristone for Uterine Leiomyomata , 2003, Obstetrics and gynecology.

[5]  D. Edwards,et al.  Mechanism of Action of Progesterone Antagonists , 2002, Experimental biology and medicine.

[6]  S. Volpi,et al.  HIV-1 Protein Vpr Suppresses IL-12 Production from Human Monocytes by Enhancing Glucocorticoid Action: Potential Implications of Vpr Coactivator Activity for the Innate and Cellular Immunity Deficits Observed in HIV-1 Infection , 2002, The Journal of Immunology.

[7]  D. Blouin,et al.  Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  A. Templeton,et al.  Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases , 2002, BJOG : an international journal of obstetrics and gynaecology.

[9]  Ø. Lidegaard,et al.  Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi‐center trial in Copenhagen county, Denmark , 2002, Acta obstetricia et gynecologica Scandinavica.

[10]  D. Baird,et al.  A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy , 2002, BJOG : an international journal of obstetrics and gynaecology.

[11]  A. Schatzberg,et al.  An open label trial of C-1073 (mifepristone) for psychotic major depression* , 2002, Biological Psychiatry.

[12]  H. Critchley,et al.  Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. , 2002, Reproduction.

[13]  A. Schatzberg,et al.  Slowing the progression of cognitive decline in alzheimer’s disease using mifepristone , 2002, Journal of Molecular Neuroscience.

[14]  P. Ho,et al.  Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation. , 2002, Human reproduction.

[15]  B. O’Malley,et al.  Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Mishell,et al.  A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. , 2002, Human reproduction.

[17]  P. Doraiswamy,et al.  Mifepristone (RU 486) for Alzheimer's disease. , 2002, Neurology.

[18]  A. Templeton,et al.  Medical management of early fetal demise using sublingual misoprostol , 2002, BJOG : an international journal of obstetrics and gynaecology.

[19]  A. Templeton,et al.  Medical management of late intrauterine death using a combination of mifepristone and misoprostol , 2002, BJOG : an international journal of obstetrics and gynaecology.

[20]  NN Sarkar.  THE POTENTIAL OF MIFEPRISTONE (RU486) AS A FEMALE CONTRACEPTIVE DRUG , 2002, International journal of clinical practice.

[21]  Sarkar Nn.  The potential of mifepristone (RU486) as a female contraceptive drug. , 2002 .

[22]  D. Baird,et al.  Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. , 2001, Human reproduction.

[23]  Alan F. Schatzberg,et al.  Rapid Reversal of Psychotic Depression Using Mifepristone , 2001, Journal of clinical psychopharmacology.

[24]  A. Templeton,et al.  Medical management of early fetal demise using a combination of mifepristone and misoprostol. , 2001, Human reproduction.

[25]  J. Schwartz,et al.  Mifepristone 100 mg in Abortion Regimens , 2001, Obstetrics and gynecology.

[26]  A. Schatzberg,et al.  Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). , 2001, The Journal of clinical endocrinology and metabolism.

[27]  S. Fielding,et al.  Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. , 2001, Contraception.

[28]  D. Baird,et al.  Second trimester medical abortion with mifepristone and gemeprost: a review of 956 cases. , 2001, Contraception.

[29]  J. Daurès,et al.  The effects of mifepristone on uterine sensitivity to oxytocin and on fetal heart rate patterns. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[30]  J. Schwartz,et al.  Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial , 2001, BJOG : an international journal of obstetrics and gynaecology.

[31]  S. Fielding,et al.  Mifepristone and misoprostol for early abortion when no gestational sac is present. , 2001, Contraception.

[32]  M. New,et al.  Long‐term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia , 2001, Clinical endocrinology.

[33]  J. Hoffmann,et al.  Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. , 2000, Journal of medicinal chemistry.

[34]  D. Baird,et al.  Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. , 2000, Contraception.

[35]  S. Fielding,et al.  Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. , 2000, JAMA.

[36]  K. Chwalisz,et al.  Progesterone receptor modulators and progesterone antagonists in women’s health , 2000, Steroids.

[37]  K. Chwalisz,et al.  Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity , 2000, Steroids.

[38]  S. Grunberg,et al.  Alterations in sex steroids and gonadotropins in post-menopausal women subsequent to long-term mifepristone administration☆ , 2000, Steroids.

[39]  P. Ho,et al.  Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. , 2000, Human reproduction.

[40]  J. Foekens,et al.  Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer , 2000, Steroids.

[41]  D. Wing,et al.  Mifepristone for Preinduction Cervical Ripening Beyond 41 Weeks' Gestation: A Randomized Controlled Trial , 2000, Obstetrics and gynecology.

[42]  K. Chwalisz,et al.  Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium , 2000, Steroids.

[43]  F. DeMayo,et al.  Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. , 2000, Science.

[44]  M. Levental,et al.  Large endometrial polyp in a patient on long‐term mifepristone therapy. , 2000, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[45]  J. Aikins,et al.  Phase II study of mifepristone (RU486) in refractory ovarian cancer. , 2000, Gynecologic oncology.

[46]  E. Jensen,et al.  Estrogen receptor (ER) , a modulator of ER in the uterus , 2000 .

[47]  G. Chatellier,et al.  A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[48]  M. Bygdeman,et al.  Induction of labor with mifepristone, ‐ A randomized, double‐blind study versus placebo , 1999, Acta obstetricia et gynecologica Scandinavica.

[49]  A. Templeton,et al.  Nonsurgical mid‐trimester termination of pregnancy: a review of 500 consecutive cases , 1999, British journal of obstetrics and gynaecology.

[50]  D. Cruickshank,et al.  Medical termination of pregnancy at 63 to 83 days gestation , 1999, British journal of obstetrics and gynaecology.

[51]  D. Mais,et al.  Estrogen Receptor β Activates the Human Retinoic Acid Receptorα -1 Promoter in Response to Tamoxifen and Other Estrogen Receptor Antagonists, but Not in Response to Estrogen , 1999 .

[52]  C. Ellertson,et al.  Use of misoprostol during pregnancy and Möbius' syndrome in infants. , 1998, The New England journal of medicine.

[53]  I. Gustavsson,et al.  Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. , 1998, The Journal of clinical endocrinology and metabolism.

[54]  A. Calder,et al.  The Effects of Mifepristone on Cervical Ripening and Labor Induction in Primigravidae , 1998, Obstetrics and gynecology.

[55]  G. Penney,et al.  An effective regimen for early medical abortion: a report of 2000 consecutive cases. , 1998, Human reproduction.

[56]  G. Boog,et al.  Cervical Ripening With Mifepristone Before Labor Induction: A Randomized Study , 1998, Obstetrics and gynecology.

[57]  K. Chwalisz,et al.  Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. , 1998, Human reproduction update.

[58]  R. Stouffer,et al.  Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity. , 1998, Human reproduction.

[59]  M. Gu,et al.  [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone]. , 1998, Zhonghua fu chan ke za zhi.

[60]  S. Yen,et al.  Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). , 1998, American journal of obstetrics and gynecology.

[61]  L. Holmes,et al.  Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy , 1998, The Lancet.

[62]  L. Adams,et al.  Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea. , 1998, Fertility and sterility.

[63]  C. Bardin,et al.  Early pregnancy termination with mifepristone and misoprostol in the United States. , 1998, The New England journal of medicine.

[64]  H. Croxatto,et al.  Effects of long-term low-dose mifepristone on reproductive function in women. , 1998, Human reproduction.

[65]  D. Edwards,et al.  The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation. , 1998, Endocrinology.

[66]  N. Weigel,et al.  The Nuclear Corepressors NCoR and SMRT Are Key Regulators of Both Ligand- and 8-Bromo-Cyclic AMP-Dependent Transcriptional Activity of the Human Progesterone Receptor , 1998, Molecular and Cellular Biology.

[67]  R. Stouffer,et al.  Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. , 1998, Human reproduction.

[68]  R. Stouffer,et al.  Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity , 1998 .

[69]  B. Murphy.  Antiglucocorticoid therapies in major depression: A review , 1997, Psychoneuroendocrinology.

[70]  M. Hahlin,et al.  Unsuccessful treatment of missed abortion with a combination of an antiprogesterone and a prostaglandin E1 analogue , 1997, British journal of obstetrics and gynaecology.

[71]  N. Benowitz,et al.  Absorption Kinetics of Misoprostol With Oral or Vaginal Administration , 1997, Obstetrics and gynecology.

[72]  A. L. Goodman,et al.  Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. , 1997, Human reproduction.

[73]  S. Khadilkar,et al.  Effect of mifepristone on folliculogenesis in women treated with recombinant FSH , 1997, Clinical endocrinology.

[74]  S. Grunberg,et al.  Alterations in the pituitary-thyroid and pituitary-adrenal axes--consequences of long-term mifepristone treatment. , 1997, Metabolism: clinical and experimental.

[75]  Martin Schmidt,et al.  RU486 is a potent inhibitor of aromatase induction in human breast adipose tissue stromal cells , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[76]  M. Sauer,et al.  Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: a hypothesis. , 1997, Fertility and sterility.

[77]  M. Ryan,et al.  The costs of treating miscarriage: a comparison of medical and surgical management , 1996, British journal of obstetrics and gynaecology.

[78]  E. Eisenhauer,et al.  Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Seokjoong Kim,et al.  Endometrial effects of RU486 in primates—Antiproliferative action despite signs of estrogen action and increased cyclin-B expression , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[80]  K. Li,et al.  [Treatment of uterine leiomyoma by two different doses of mifepristone]. , 1996, Zhonghua fu chan ke za zhi.

[81]  D. Edwards,et al.  16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[82]  M. Breckwoldt,et al.  Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms. , 1996, Human reproduction.

[83]  G. Hodgen,et al.  Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. , 1996, The Journal of clinical endocrinology and metabolism.

[84]  A. Mathers,et al.  Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin. , 1996, European journal of obstetrics, gynecology, and reproductive biology.

[85]  M. Choolani,et al.  Termination of Early Human Pregnancy with Either 50 mg or 200 mg Single Oral Dose of Mifepristone (RU486) in Combination with Either 0.5 mg or 1.0 mg Vaginal Gemeprost* , 1996, The Australian & New Zealand journal of obstetrics & gynaecology.

[86]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[87]  D. Baird,et al.  Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth , 1995, Clinical endocrinology.

[88]  S. Yen,et al.  Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. , 1995, Fertility and sterility.

[89]  D. Baird,et al.  Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. , 1995, Human reproduction.

[90]  A. Templeton,et al.  Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. , 1995, The New England journal of medicine.

[91]  T. Parmley,et al.  Endometrial effects of long-term low-dose administration of RU486. , 1995, Fertility and sterility.

[92]  J. Norman.  Uterine rupture during therapeutic abortion in the second trimester using mifepristone and prostaglandin , 1995, British journal of obstetrics and gynaecology.

[93]  M. Hahlin,et al.  Expectant management of first-trimester spontaneous abortion , 1995, The Lancet.

[94]  S. Parthasarathy,et al.  Antioxidant: a new role for RU-486 and related compounds. , 1994, The Journal of clinical investigation.

[95]  H. Tanaka,et al.  The effects of hydrocortisone and RU486 (mifepristone) on iodide uptake in porcine thyroid cells in primary culture. , 1994, Endocrinology.

[96]  R. Bigsby,et al.  Estrogenic effects of the antiprogestin onapristone (ZK98.299) in the rodent uterus. , 1994, American journal of obstetrics and gynecology.

[97]  J. Neulen,et al.  Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. , 1994, Human reproduction.

[98]  A. Murphy,et al.  RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. , 1994, Current opinion in obstetrics & gynecology.

[99]  R. Frydman,et al.  Mifepristone for labour induction after previous caesarean section , 1994, British journal of obstetrics and gynaecology.

[100]  S. Grunberg.  Role of antiprogestational therapy for meningiomas. , 1994, Human reproduction.

[101]  P. Ho,et al.  Termination of pregnancy with reduced doses of mifepristone , 1994, BMJ.

[102]  D. McDonnell,et al.  RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. , 1994, The Journal of biological chemistry.

[103]  J. Rubin,et al.  Progesterone-dependent expression of keratinocyte growth factor mRNA in stromal cells of the primate endometrium: keratinocyte growth factor as a progestomedin , 1994, The Journal of cell biology.

[104]  W. Vale,et al.  Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. , 1994, Fertility and sterility.

[105]  R. Brenner,et al.  RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta). , 1994, The Journal of clinical endocrinology and metabolism.

[106]  C. Bardin,et al.  Clinical pharmacology of RU 486--an antiprogestin and antiglucocorticoid. , 1993, Contraception.

[107]  C. Bardin,et al.  Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. , 1993, The New England journal of medicine.

[108]  C. Kim,et al.  Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. , 1993, American journal of medical genetics.

[109]  K. Burry,et al.  Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. , 1993, American journal of obstetrics and gynecology.

[110]  D. Edwards,et al.  The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[111]  K. Horwitz,et al.  Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. , 1993, The Journal of biological chemistry.

[112]  W. Kühnel,et al.  Morphology of the rat uterus after long-term treatment with progesterone antagonists. , 1993, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[113]  R. Frydman,et al.  Mifepristone (RU 486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial. , 1993, Human reproduction.

[114]  H. Croxatto,et al.  Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. , 1993, Human reproduction.

[115]  S. Yen,et al.  Regression of uterine leiomyomata in response to the antiprogesterone RU 486. , 1993, The Journal of clinical endocrinology and metabolism.

[116]  S. Tarlo,et al.  Medical management of missed abortion and anembryonic pregnancy. , 1992, BMJ.

[117]  R. Frydman,et al.  Labor induction in women at term with mifepristone (RU 486): A double‐blind, randomized, placebo‐controlled study , 1992, Obstetrics and gynecology.

[118]  H. M. Beier,et al.  Luteal control of endometrial receptivity and its modification by progesterone antagonists. , 1992, Endocrinology.

[119]  H. Coelho,et al.  Misoprostol and congenital malformations , 1991, The Lancet.

[120]  S. Lamberts,et al.  The endocrine effects of long-term treatment with mifepristone (RU 486). , 1991, The Journal of clinical endocrinology and metabolism.

[121]  L. L. Stevenson,et al.  Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. , 1991, Journal of neurosurgery.

[122]  G. Ryffel,et al.  Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. , 1991, Nucleic acids research.

[123]  J. Foekens,et al.  Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[124]  G. Chrousos,et al.  Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects. , 1990, The Journal of clinical endocrinology and metabolism.

[125]  D. Cabrol,et al.  Induction of labor with mifepristone (RU 486) in intrauterine fetal death. , 1990, American journal of obstetrics and gynecology.

[126]  I. Mackenzie,et al.  The placental transfer of mifepristone (RU 486) during the second trimester and its influence upon maternal and fetal steroid concentrations , 1990 .

[127]  G. Romieu,et al.  The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. , 1986, Bulletin du cancer.

[128]  B. Sun,et al.  Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen and RU 486. , 1986, Endocrinology.

[129]  D. Cabrol,et al.  INDUCTION OF LABOUR WITH MIFEPRISTONE AFTER INTRAUTERINE FETAL DEATH , 1985, The Lancet.

[130]  G. Chrousos,et al.  Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. , 1985, The Journal of clinical endocrinology and metabolism.

[131]  D. Philibert.  RU 38486: An Original Multifaceted Antihormone in Vivo , 1984 .

[132]  M. Mcphail.  The assay of progestin , 1934, The Journal of physiology.

[133]  D. Baird,et al.  Effect of long-term treatment with low-dose mifepristone on the endometrium. , 2003, Human reproduction.

[134]  A. Templeton,et al.  A randomized comparison of medical abortion and surgical vacuum aspiration at 10-13 weeks gestation. , 2002, Human reproduction.

[135]  I. Mackenzie,et al.  A comparative study of surgical and medical procedures: 932 pregnancy terminations up to 63 days gestation. , 2001, Human reproduction.

[136]  J. Gustafsson,et al.  Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[137]  I. Spitz.  Progestins, Progesterone Receptor Modulators, and Progesterone Antagonists. Progesterone, progestins and antiprogestins in the next millennium, Jerusalem, Israel, 31 August-3 September, 1999. , 2000 .

[138]  D. Mais,et al.  Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. , 1999, Molecular endocrinology.

[139]  D. McDonnell,et al.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.

[140]  P. Giangrande,et al.  The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. , 1999, Recent progress in hormone research.

[141]  P. Franks,et al.  Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. , 1999, Contraception.

[142]  Urquhart,et al.  The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study--final results. , 1997, Contraception.

[143]  H. Croxatto,et al.  Antiprogestins: mechanism of action and contraceptive potential. , 1996, Annual review of pharmacology and toxicology.

[144]  E. Baulieu,et al.  Treatment of endometriosis with the antiprogesterone mifepristone (RU486) , 1996, Fertility and sterility.

[145]  E. Baulieu,et al.  Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected]. , 1995, International journal of fertility and menopausal studies.

[146]  M. Donaldson,et al.  Clinical Applications of Mifepristone (RU 486) and Other Antiprogestins , 1993 .

[147]  I. Mackenzie,et al.  The placental transfer of mifepristone (RU 486) during the second trimester and its influence upon maternal and fetal steroid concentrations. , 1990, British journal of obstetrics and gynaecology.

[148]  D. Pfaff,et al.  The brain as a target for steroid hormone action. , 1979, Annual review of neuroscience.

[149]  D. Chattopadhyaya.  Medical termination of pregnancy. , 1972, Swasth hind.